What the COVID-19 pandemic revealed about intellectual property

An Update on SARS-CoV-2 Clinical Trial Results—What We Can Learn for the Next Pandemic

“…In the COVID-19 pandemic, the existing international laws and intellectual property practices failed to ensure equitable access to vaccines and therapeutics globally [ 286 ]. During the SARS-CoV-2 pandemic, companies appear to have financed their development efforts on the back of large procurement contracts with governments, rather than on the prospect of intellectual property, providing a useful case study for pandemic preparedness [ 287 ].…”

Disclosure of patenting activities within scientific publications as potential conflicts-of-interest: Evidences from biomedical literature

“…COVID-19 appears as the obvious topic to perform a test about COIS and COPIS completeness. Even if the pandemics has somehow modified the attitudes towards intellectual property, drug development, and health issues [65], a validation of COI information is made more feasible since the full-text format for COVID-related publications is freely available, even for journals generally requiring a subscription [66]. for PubMed records in general (Fig.…”

Proposals to waive intellectual property rights for pandemic response products in the World Health Organization pandemic accord need Australia's support

“…Intellectual property rights can affect equitable access to COVID‐19 vaccines, diagnostics and treatments in various ways 10 . For example, a single rapid antigen test may have copyright, trademarks, trade secrets and patents attached.…”